Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786969 | 1.00 | PLA2G1B (0.43) | PLA2G1BPLA2G2ALMNADNM1TSHR | |
| SCHEMBL20214869 | 0.95 | PLA2G1B (0.41) | PLA2G1BPLA2G2ALMNADNM1TSHR | |
| SCHEMBL30432059 | 0.91 | PLA2G1B (0.38) | PLA2G1BPLA2G2ALMNADNM1TSHR | |
| SCHEMBL29286849 | 0.91 | PLA2G1B (0.41) | PLA2G1BPLA2G2ALMNADNM1TSHR | |
| SCHEMBL29286804 | 0.91 | PLA2G1B (0.41) | PLA2G1BPLA2G2ALMNADNM1TSHR | |
| SCHEMBL116821 | 0.91 | PLA2G1B (0.41) | PLA2G1BPLA2G2ALMNADNM1TSHR | |
| SCHEMBL21216971 | 0.91 | DNM1 (0.42) | PLA2G1BPLA2G2ALMNADNM1OPRM1 | |
| SCHEMBL9514238 | 0.90 | DNM1 (0.46) | PLA2G1BPLA2G2ALMNADNM1TSHR | |
| SCHEMBL10685373 | 0.90 | DNM1 (0.46) | PLA2G1BPLA2G2ALMNADNM1TSHR | |
| SCHEMBL2419404 | 0.90 | DNM1 (0.46) | PLA2G1BPLA2G2ALMNADNM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | PLA2G1B 2185/4885PLA2G2A 1768/4885LMNA 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.